Karine has more than 25 years’ management experience in both industry and biomedical research institutes. She was CEO of the French Foundation for Hearing for 3 years and was co-secretary general of the Imagine Institute of Genetic Diseases for 10 years, where she structured, developed, and ensured funds raising for the institute. As a Doctor of Pharmacy and a HEC Business School graduate, she brings an extended managing experience in both the public and the private sectors. She has 12-year international experience in international marketing in LVMH, L’Oreal, and Chanel.
Marina is an internationally recognized pioneer in cell and gene therapy (+300 articles), a Member of the American Medical Academy, and recipient of the Beutler ASH award, the Prix Irene Joliot Curie, and Grand prix de l’Académie de Médicine. She directs the Biotherapy Clinical Investigation Center and the Biotherapy Department and she is Head of the Gene Therapy clinical department at Necker Children’s Hospital, Paris, France.
Isabelle is internationally recognized for her work on immunodeficiency and T-cell differentiation. She heads the INSERM research laboratory working on human lympho-hematopoiesis at the Imagine Institute of genetic diseases, Necker Enfants Malades hospital Campus, Paris. Dr André has extensive experience with T-cell biology and differentiation and is the inventor of the ex vivo lymphoid niche proprietary technology developed by Smart Immune, conducting all pre-clinical studies and associated technological innovations.
Olivier earned an engineering degree in biotechnology from ENSTBB and a PhD in cell and molecular biology from Paris Diderot University. He has been working for more than 20 years in the field of biotherapies including the production of recombinant proteins with BioProtein Technologies and gene therapy programs at bluebird bio both in France and in the USA. Olivier is a board member of the French Society of Gene and Cell Therapy, co-president of the think tank Gene & Cell Therapy Institute, co-founder of Biotherapy Partners and currently VP, head of R&D at Smart Immune.
Pierre brings over 30 years of experience in process automation of allogeneic and autologous CAR-Treg, Treg, viral vectors and vaccines. Prior to joining Smart Immune, he held key managerial roles overseeing production, pharmaceutical development and quality control departments at multiple pharma and biotech companies such as Aventis-Pasteur (Sanofi), Octapharma, Transgene, TxCell, and most recently, Sangamo Therapeutics. Pierre holds a PharmD from the Mérieux Institute in France.
As the former Head of Clinical Development and Medical Affairs and Vice President of Celyad Oncology, Dr Frederic Lehmann defined the strategic vision and contributed to securing a number of autologous and allogeneic engineered T-cell therapy IND candidates. He also spent 12 years at GSK in several roles including Head of the Early Clinical Development Business Unit for Cancer Immunotherapeutics in the company’s Vaccine Division.